787.F SELVITA S.A. SER.B ZY-80
- Market cap
- EUR 66.9M
- P/E
- -
- P/B
- 0.93x
- ROE
- -5.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 787.F undervalued?
Graham numberThe Graham number of SELVITA S.A. SER.B ZY-80 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SELVITA S.A. SER.B ZY-80 fundamental analysis
No fundamental analysis for SELVITA S.A. SER.B ZY-80 yet.
SELVITA S.A. SER.B ZY-80 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SELVITA S.A. SER.B ZY-80
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, mo…
Full company profileSELVITA S.A. SER.B ZY-80 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SELVITA S.A. SER.B ZY-80 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 311M | 361M | 347M | 342M | 364M | 316M |
| Gross Profit | 251M | 293M | 276M | 268M | 293M | 247M |
| Operating Income | 26.1M | 39.9M | 16.7M | -488K | 12.5M | -3.45M |
| EBITDA | - | 76.1M | 123M | 55.3M | 62.7M | 42.2M |
| Net Income | 14.9M | 30.3M | 69.9M | -6.10M | 813K | -17.0M |
| EPS | 0.81 | 1.65 | 3.81 | -0.33 | 0.04 | -0.93 |
| Balance Sheet | ||||||
| Total Assets | 456M | 585M | 636M | 642M | 598M | 583M |
| Total Liabilities | 250M | 312M | 309M | 320M | 276M | 267M |
| Shareholders' Equity | 197M | 262M | 327M | 322M | 322M | 315M |
| Cash & Short-term Investments | 83.6M | 74.2M | 52.7M | 22.5M | 24.2M | 16.6M |
| Cash Flow | ||||||
| Operating Cash Flow | 85.4M | 75.4M | 79.0M | 64.1M | 73.3M | 4.32M |
| Capital Expenditure | 25.5M | 102M | 73.9M | 18.7M | 7.15M | 11.9M |
| Free Cash Flow | 59.9M | -26.2M | 5.05M | 45.4M | 66.1M | -7.55M |
| Ratios | ||||||
| ROE | 7.6% | 11.6% | 21.4% | -1.9% | 0.3% | -5.4% |
| ROA | 3.3% | 5.2% | 11.0% | -0.9% | 0.1% | -2.9% |
| Net Profit Margin | 4.8% | 8.4% | 20.2% | -1.8% | 0.2% | -5.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SELVITA S.A. SER.B ZY-80 dividends
SELVITA S.A. SER.B ZY-80 has not paid dividends in the last 5 fiscal years.
Who owns SELVITA S.A. SER.B ZY-80
- Insiders 21.18%
- Institutions 27.31%
- Public & others 51.51%
- Shares outstanding 18.4M
- Free float 9.75M
SELVITA S.A. SER.B ZY-80 company profile
- Company name
- SELVITA S.A. SER.B ZY-80
- Ticker
- 787.F
- ISIN
- PLSLVCR00029
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 899
- Fiscal year end
- December
- Address
- Hexagon, Kraków, Poland, 30-394
- Phone
- 48 123 00 50 01
- Website
- selvita.com
About SELVITA S.A. SER.B ZY-80
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic and target-focused profiling, vitro safety platform, translational research and biomarkers, and specialized discovery platform; vivo models, non-GLP toxicology, histopathology, and tissue biobank; ADME and pharmacokinetic study, bioanalysis, DMPK strategy, and modeling; and proteomic, transcriptomic, spatial mass spectrometry imaging, and data analysis services. It also provides antibody discovery, developability, antibody characterization, antibody engineering, and other modalities. In addition, the company offers active substance, raw materials and drug products comprising scale-up and process chemistry, solid state characterization, CMC analytical support, analytical methods development and validation, nitrozoamines and other impurities, impurities identification, quality control and QP release, stability studies, formulation development, and clinical supply GMP manufacturing; extractables and leachables, and packaging and functionality; bioanalysis of small molecules; and regulatory affairs. Further, it provides method development and validation, physicochemical properties determination, five batch analysis, one batch analysis, impurities identification, certification, stability studies, process chemistry, and solid state characterization services. The company was formerly known as Selvita CRO S.A. and changed its name to Selvita S.A. in October 2019. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland.
SELVITA S.A. SER.B ZY-80 management
10- Mr. Rafal Piotr Chwast M.Sc.Chairman of Management Board & CEO
- Mr. Boguslaw Stanislaw Sieczkowski M.B.A.VP of the Management Board & Chief Commercial Officer
- Dr. Milosz Kazimierz Gruca Ph.D.Global Head of Drug Development, Executive VP & Vice President of Management Board
- Mr. Dariusz Tomasz KurdasCFO & Member of the Management Board
- Mr. Dawid Patryk RadziszewskiGeneral Counsel & Member of the Management Board
- Natalia Walas - MarcinekExecutive Officer
- Marija Gradecak GalovicExecutive Officer
- Anna LejaExecutive Officer
- Mr. Tomasz NarojczykExecutive Officer
- Dr. Jasna PadovanGlobal Head of Drug Discovery & Member of Management Board